Literature DB >> 18676848

Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

Dalit Barkan1, Hynda Kleinman, Justin L Simmons, Holly Asmussen, Anil K Kamaraju, Mark J Hoenorhoff, Zi-yao Liu, Sylvain V Costes, Edward H Cho, Stephen Lockett, Chand Khanna, Ann F Chambers, Jeffrey E Green.   

Abstract

Metastatic breast cancer may emerge from latent tumor cells that remain dormant at disseminated sites for many years. Identifying mechanisms regulating the switch from dormancy to proliferative metastatic growth has been elusive due to the lack of experimental models of tumor cell dormancy. We characterized the in vitro growth characteristics of cells that exhibit either dormant (D2.0R, MCF-7, and K7M2AS1.46) or proliferative (D2A1, MDA-MB-231, and K7M2) metastatic behavior in vivo. Although these cells proliferate readily in two-dimensional culture, we show that when grown in three-dimensional matrix, distinct growth properties of the cells were revealed that correlate to their dormant or proliferative behavior at metastatic sites in vivo. In three-dimensional culture, cells with dormant behavior in vivo remained cell cycle arrested with elevated nuclear expression of p16 and p27. The transition from quiescence to proliferation of D2A1 cells was dependent on fibronectin production and signaling through integrin beta1, leading to cytoskeletal reorganization with filamentous actin (F-actin) stress fiber formation. We show that phosphorylation of myosin light chain (MLC) by MLC kinase (MLCK) through integrin beta1 is required for actin stress fiber formation and proliferative growth. Inhibition of integrin beta1 or MLCK prevents transition from a quiescent to proliferative state in vitro. Inhibition of MLCK significantly reduces metastatic outgrowth in vivo. These studies show that the switch from dormancy to metastatic growth may be regulated, in part, through epigenetic signaling from the microenvironment, leading to changes in the cytoskeletal architecture of dormant cells. Targeting this process may provide therapeutic strategies for inhibition of the dormant-to-proliferative metastatic switch.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676848      PMCID: PMC2561279          DOI: 10.1158/0008-5472.CAN-07-6849

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.

Authors:  C J Aslakson; F R Miller
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

Review 2.  Calcium/calmodulin-dependent protein kinases.

Authors:  A C Nairn; M R Picciotto
Journal:  Semin Cancer Biol       Date:  1994-08       Impact factor: 15.707

Review 3.  Signal transduction and regulation in smooth muscle.

Authors:  A P Somlyo; A V Somlyo
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

4.  Metastasis-suppressed C8161 melanoma cells arrest in lung but fail to proliferate.

Authors:  S F Goldberg; J F Harms; K Quon; D R Welch
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1.

Authors:  P Henriet; Z D Zhong; P C Brooks; K I Weinberg; Y A DeClerck
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.

Authors:  K Pantel; G Schlimok; S Braun; D Kutter; F Lindemann; G Schaller; I Funke; J R Izbicki; G Riethmüller
Journal:  J Natl Cancer Inst       Date:  1993-09-01       Impact factor: 13.506

7.  Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth.

Authors:  V L Morris; S Koop; I C MacDonald; E E Schmidt; M Grattan; D Percy; A F Chambers; A C Groom
Journal:  Clin Exp Metastasis       Date:  1994-11       Impact factor: 5.150

8.  The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells.

Authors:  E W Thompson; N Brünner; J Torri; M D Johnson; V Boulay; A Wright; M E Lippman; P S Steeg; R Clarke
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

9.  Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines.

Authors:  V L Morris; A B Tuck; S M Wilson; D Percy; A F Chambers
Journal:  Clin Exp Metastasis       Date:  1993-01       Impact factor: 5.150

10.  Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.

Authors:  V M Weaver; O W Petersen; F Wang; C A Larabell; P Briand; C Damsky; M J Bissell
Journal:  J Cell Biol       Date:  1997-04-07       Impact factor: 10.539

View more
  192 in total

Review 1.  Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression.

Authors:  Pepper Schedin; Patricia J Keely
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

2.  Modeling metastasis biology and therapy in real time in the mouse lung.

Authors:  Arnulfo Mendoza; Sung-Hyeok Hong; Tanasa Osborne; Mohammed A Khan; Kirk Campbell; Joseph Briggs; Ananth Eleswarapu; Lauren Buquo; Ling Ren; Stephen M Hewitt; El Habib Dakir; El-H Dakir; Susan Garfield; Renard Walker; Glenn Merlino; Jeffrey E Green; Kent W Hunter; Lalage M Wakefield; Chand Khanna
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

3.  Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion.

Authors:  Gunjan Malik; Lynn M Knowles; Rajiv Dhir; Shuping Xu; Shuting Yang; Erkki Ruoslahti; Jan Pilch
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

4.  Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression.

Authors:  Thaiz Ferraz Borin; Ali Syed Arbab; Gabriela Bottaro Gelaleti; Lívia Carvalho Ferreira; Marina Gobbe Moschetta; Bruna Victorasso Jardim-Perassi; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Verena Benedick Coimbra; Vanessa Alves Fabri; Juliana Garcia de Oliveira; Debora Aparecida Pires de Campos Zuccari
Journal:  J Pineal Res       Date:  2015-10-20       Impact factor: 13.007

Review 5.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

6.  Role of connexins in metastatic breast cancer and melanoma brain colonization.

Authors:  Konstantin Stoletov; Jan Strnadel; Erin Zardouzian; Masashi Momiyama; Frederick D Park; Jonathan A Kelber; Donald P Pizzo; Robert Hoffman; Scott R VandenBerg; Richard L Klemke
Journal:  J Cell Sci       Date:  2013-01-15       Impact factor: 5.285

7.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

8.  Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model.

Authors:  Y Jeffrey Wu; Leslie L Muldoon; Seymur Gahramanov; Dale F Kraemer; Deborah J Marshall; Edward A Neuwelt
Journal:  J Neurooncol       Date:  2012-07-29       Impact factor: 4.130

9.  TGF-β upregulates miR-181a expression to promote breast cancer metastasis.

Authors:  Molly A Taylor; Khalid Sossey-Alaoui; Cheryl L Thompson; David Danielpour; William P Schiemann
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

10.  In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.

Authors:  Calogero D'Alessandria; Karolin Pohle; Florian Rechenmacher; Stefanie Neubauer; Johannes Notni; Hans-Jürgen Wester; Markus Schwaiger; Horst Kessler; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.